Publication
What M&A trends will transform the 2024 insurance landscape?
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Canada | Publication | October 2023
Norton Rose Fulbright lawyers Kristin Wall, Randy Sutton, Veronique Barry, Christopher Guerreiro and Sarah Pennington contributed the Canada chapters to the Practical Law Life Sciences Global Guide on commercialization and regulation. The Guide is published in a Q&A format by Thomson Reuters, which is a leading global platform for trusted, up-to-date legal know how across all major practice areas.
Life Sciences Commercialisation in Canada: Overview
The Q&A Guide to life sciences commercialisation in Canada provides an overview of Canada’s life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.
Life Sciences Regulation in Canada: Overview
The Q&A guide to life sciences regulation in Canada reviews the main legislation governing pharmaceuticals in Canada. The guide provides an overview of key practical issues, including clinical trials, manufacturing, marketing, abridged procedures, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, and natural health products.
Publication
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023